ArticleBreast cancer research : BCR2026
Germline APOE ε2 homozygosity and reduced risk of breast cancer: a population-based cohort study.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We evaluated whether Apolipoprotein E (APOE) ε2 homozygosity, a germline variant associated with lower LDL cholesterol, is linked to reduced risk of breast cancer. We analyzed data from 234,857 cancer-free and dementia-free women in the UK Biobank. APOE genotypes were classified as ε2 homozygotes, ε2 heterozygotes, and non-ε2 carriers. Incident breast cancer was assessed via national registry linkage. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs). Subgroup analyses were conducted by lifestyle, metabolic, and female-specific factors. Over a median follow-up of 12.3 years, 7,961 first primary breast cancers occurred. Compared to non-ε2 carriers, ε2 homozygotes had significantly lower breast cancer risk (HR, 0.64; 95% CI 0.45-0.90). The protective association of ε2/ε2 was stronger in participants with smoking history. APOE ε2 homozygosity was associated with reduced risk of breast cancer, particularly under inflammatory stress. These findings suggest that genetically determined lipid and inflammatory regulation may influence breast cancer susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.